請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/24303完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 忻凌偉 | |
| dc.contributor.author | Hung-Wei Chen | en |
| dc.contributor.author | 陳虹瑋 | zh_TW |
| dc.date.accessioned | 2021-06-08T05:21:19Z | - |
| dc.date.copyright | 2005-08-26 | |
| dc.date.issued | 2005 | |
| dc.date.submitted | 2005-07-26 | |
| dc.identifier.citation | (1) Zee-Cheng, R. K.; Cheng, C. C. Antineoplastic agents. Structure-activity relationship study of bis(substituted aminoalkylamino)anthraquinones. J. Med. Chem. 1978, 21, 291-294.
(2) Barasch, D.; Zipori, O.; Ringel, I.; Ginsburg, I.; Samuni, A.; Katzhendler, J. Novel anthraquinone derivatives with redox-active functional groups capable of producing free radicals by metabolism: are free radicals essential for cytotoxicity? Eur. J. Med. Chem. 1999, 34, 597-615. (3) Routier, S.; Cotelle, N.; Catteau, J. P.; Bernier, J. L.; Waring, M. J.; Riou, J. F.; Bailly, C. Salen-anthraquinone conjugates. Synthesis, DNA-binding and cleaving properties, effects on topoisomerases and cytotoxicity. Bioorg. Med. Chem. 1996, 4, 1185-1196. (4) Krapcho, A. P.; Getahun, Z.; Avery, K. L., Jr.; Vargas, K. J.; Hacker, M. P.; Spinelli, S.; Pezzoni, G.; Manzotti, C. Synthesis and antitumor evaluations of symmetrically and unsymmetrically substituted 1,4-bis[(aminoalkyl)amino]anthracene-9,10-diones and 1,4-bis[(aminoalkyl)amino]-5,8-dihydroxyanthracene-9,10-diones. J. Med. Chem. 1991, 34, 2373-2380. (5) Fox, E. J. Mechanism of action of mitoxantrone. Neurology 2004, 63, S15-18. (6) Giles, G.I.; Sharma, R. Solid phase synthesis of anthraquinone peptides and their evaluation as topoisomerase I inhibitors. J. Pept. Sci. 2005 (in press). (7) Denny, W. A.; Wakelin, L. P. G. Kinetics of the binding of mitoxantrone, ametantrone and and analogues to DNA: relationship with binding mode and anti-tumor activity. Anti-Cancer Drug Des. 1990, 5, 189-200. (8) Morier-Teissier, E.; Boitte, N.; Helbecque, N.; Bernier, J. L.; Pommery, N.; Duvalet, J. L.; Fournier, C.; Hecquet, B.; Catteau, J. P.; Henichart, J. P. Synthesis and antitumor properties of an anthraquinone bisubstituted by the copper chelating peptide Gly-Gly-L-His. J. Med. Chem. 1993, 36, 2084-2090. (9) Gatto, B.; Zagotto, G.; Sissi, C.; Cera, C.; Uriarte, E.; Palu, G.; Capranico, G.; Palumbo, M. Peptidyl anthraquinones as potential antineoplastic drugs: synthesis, DNA binding, redox cycling, and biological activity. J. Med. Chem. 1996, 39, 3114-3122. (10) Pors, K.; Paniwnyk, Z.; Ruparelia, K. C.; Teesdale-Spittle, P. H.; Hartley, J. A.; Kelland, L. R.; Patterson, L. H. Synthesis and biological evaluation of novel chloroethylaminoanthraquinones with potent cytotoxic activity against cisplatin-resistant tumor cells. J. Med. Chem. 2004, 47, 1856-1859. (11) Skladanowski, A.; Konopa, J. Mitoxantrone and ametantrone induce interstrand cross-links in DNA of tumour cells. Br. J. Cancer 2000, 82, 1300-1304. (12) Silverman, R. B. DNA and DNA-Intercalative Agents. In The Organic Chemistry of Drug Design and Action, Academic Press, 1992. (13) Burgess, K.; Ibarzo, J.;Russell, D. H.; Shin, H.; Shitangkoon, A.; Totani, R.; Zhang, A. J. Solid Phase Syntheses of Oligoureas. J. Am. Chem. Soc. 1997, 119, 1556-1564. (14) Kim, J. Y.; Bi, Y.; Paikoff, S. J.; Schultz, P. G. The Solid Phase Synthesis of Oligoureas. Tetrahedron Lett. 1996, 37, 5305-5308. (15) Kruijtzer, J. A.; Lefeber, J.; Liskamp, M. J. Approaches to the Synthesis of Ureapeptoid Peptidomimetics. Tetrahedron Lett. 1997, 38, 5335-5338. (16) Boeijen, A.; Liskamp, M. J. Solid-Phase Synthesis of Oligourea Peptidomimetics. Euro. J. Org. Chem. 1999, 1999, 2127-2135. (17) Burgess, K.; Ibrazo, J.; Russell, D. H.; Shin, H.; Shitangkoon, A.; Totani, R.; Zhang, A. J. Solid-phase synthesis of unnatural biopolymers containing repeating urea units. Angew. Chem. Int. Ed. Engl. 1995, 34, 907-909. (18) Mengfei, H.; James, K. K. C.; Nancy, T. A convenient synthesis of chiral N-Boc-amino ethers as potential peptide bond surrogate units. Tetrahedron Lett. 1993, 34, 6513-6516. (19) Boeijen, A.; Ameijde J. V.; Liskamp, M. J. Solid-phase synthesis of oligourea peptidomimetics employing the Fmoc protection strategy. J. Org. Chem. 2001, 66, 8454-8462. (20) Marc, R.; Muriel, L.; Sylvie, D.; Annie, H.; Jean, M. A facile synthesis of chiral N-protected b-amino alcohols. Tetrahedron Lett. 1991, 32, 923-926. (21) Brouwer, A. J.; Monnee, C. F.; Liskamp, M. J. An efficient synthesis of N-protected ?aminoethanesulfonyl chlorides: versatile building blocks for the synthesis of oligopeptidosulfonamides. Synthesis 2000, 11, 1579-1584. (22) Chen, W. R. Design and synthesis of amido- and carbamoyl-anthraquinones as potential antitumor agents. 國立台灣大學醫學院藥學研究所碩士論文,July 2005. (23) Laschat, S.; Frohlich, R.; Wibbeling, B. Preparation of 2,3,4-Trisubstituted Piperidines by a Formal Hetero-Ene Reaction of Amino Acid Derivatives. J. Org. Chem. 1996, 61, 2829-2838. (24) Abdel-Magid, A. F.; Carson, K. G.; Harris, B. D.; Maryanoff, C. A.; Shah, R. D. Reductive Amination of Aldehydes and Ketones with Sodium Triacetoxyborohydride. Studies on Direct and Indirect Reductive Amination Procedures(1). J. Org. Chem. 1996, 61, 3849-3862. (25) Giancarlo, V.; Paola, G.; Elena, P.; Angelo, G. G. Sodium bodohydride: A versatile reagent in the reductive N-monoalkylation of α-amino acids and α-amino methyl esters. Can. J. Chem. 2002, 80, 779-788. (26) Bailly, C.; Routier, S.; Bernier, J. L.; Waring, M. J. DNA recognition by two mitoxantrone analogues: influence of the hydroxyl groups. FEBS Lett. 1996, 379, 269-272. (27) Routier, S.; Bernier, J. L.; Catteau, J. P.; Riou, J. F.; Bailly, C. Synthesis, DNA binding, topoisomerase II inhibition and cytotoxicity of two guanidine-containing anthracene-9,10-diones. Anticancer Drug Des. 1998, 13, 407-415. (28) Collier, D. A.; Neidle, S. Synthesis, molecular modeling, DNA binding, and antitumor properties of some substituted amidoanthraquinones. J. Med. Chem. 1988, 31, 847-857. (29) Lin, C. C. Synthetic studies on the monomers for oligourea peptidomimetics. 國立台灣大學醫學院藥學研究所碩士論文, July 2003. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/24303 | - |
| dc.description.abstract | 蒽二酮為許多重要抗癌藥物的核心骨架,如 mitoxantrone 等。Mitoxantrone 為經由合成得到的胺基蒽醌類化合物,臨床上用來治療白血病等。Mitoxantrone 的可能抗癌機轉包括有嵌入去氧核醣核酸鹼基對中,抑制 topoisomerase II 和產生自由基。本研究的目的在於設計並合成具有比 mitoxantrone 較高抗癌活性和較低毒性的一系列新穎蒽醌類化合物,在本實驗室的合成策略中,我們保留了 mitoxantrone 的平面三環結構及雙-[(2-胺乙基)胺基]支鏈,這支鏈可作為和胺基酸的連接部分,而接上胺基酸已證實對於增加藥物的專一性是非常有用的。本實驗室中已成功合成出一系列的醯胺基蒽醌類化合物,此種化合物中蒽二酮結構經由醯胺鍵連結胺基酸。然而,醯胺鍵易受蛋白質酶水解影響,因而已有大量的注意力集中在將醯胺鍵部份置換成尿素骨架。由於骨架結構上的差異,尿素架構聚仿胜肽在形成氫鍵的性質、脂溶性、穩定性和構形的彈性皆異於醯胺骨架之聚仿胜肽。此外,尿素架構聚仿胜肽不易受蛋白質水解影響。而為了合成新一系列具有尿素骨架的脲基蒽醌類化合物,本實驗室利用微波加熱器來協助開發更有效率的尿素單體合成方法。此外,我們亦試著開發和 mitoxantrone 同類的胺基蒽醌類化合物。本論文中開發的數個蒽醌類化合物,在不同的人類癌細胞株中表現有意義的細胞毒殺作用,而更進一步的藥理評估正在進行中。 | zh_TW |
| dc.description.abstract | The anthracenedione is the nucleus of several important antitumor agents such as mitoxantrone. Mitoxantrone is a synthetic aminoanthraquinone used in clinic for the treatment of leukemia etc. The possible mechanisms of mitoxantrone include intercalation into DNA base pairs, inhibition of topoisomerase II, and production of free radicals. Our aim is to synthesize novel anthraquinones which could show higher activity and lower toxicity than mitoxantrone. In our strategy, we keep the planar tricyclic system and the –[(aminoethyl)amino] side chains of mitoxantrone. The side chains could be the linkers upon which the amino acids could be introduced. The presence of amino acids might prove very useful in terms of drug specificity. We have synthesized a series of amidoanthraquinones in which the anthracenedione structure are linked to amino acids via amide linkages. However, the amide backbone is not stable to proteolytic hydrolysis. Recently an increasing amount of attention has been focused on the application of the urea moiety as a replacement for the amide bond in peptidomimetics. Due to the difference in backbone structure, oligoureas may differ from peptides in hydrogen-bonding properties, lipophilicity, stability, and conformational flexibility. Moreover, oligoureas are resistant to proteolytic hydrolysis. These characteristics of oligoureas may be useful in improving pharmacokinetic properties relative to peptides. In order to synthesize the ureidoanthraquinines, we developed a convenient general method with microwave-assisted for the synthesis of urea monomers. Besides, we are trying to develop the aminoanthraquinones as mitoxantrone derivatives. Several novel anthraquinones showed significant cytotoxicity against different human cancer cell lines. Further pharmacological evaluation of these promising compounds is recently in progress. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-08T05:21:19Z (GMT). No. of bitstreams: 1 ntu-94-R92423001-1.pdf: 11372891 bytes, checksum: b84c99bbdbbec773ba497ec05ab560e5 (MD5) Previous issue date: 2005 | en |
| dc.description.tableofcontents | 中文摘要 V
英文摘要 VI 背景 1 研究目的 11 結果與討論 1.合成部份 1.1尿素單體之合成 12 1.2醯胺基蒽醌類化合物之合成 19 1.3脲基蒽醌類化合物之合成 25 1.4胺基蒽醌類化合物之合成 26 2.藥理部分 31 結論 35 實驗部分 1.試劑與溶劑來源 36 2.一般儀器與方法 38 3.合成步驟與分析數據 40 參考文獻 99 附圖 104 路徑目錄 路徑一、尿素單體的典型合成方法之一 7 路徑二、尿素單體的典型合成方法之二 8 路徑三、尿素單體之逆合成分析 12 路徑四、化合物2之合成途徑 13 路徑五、化合物3之合成途徑 13 路徑六、化合物4之合成途徑 14 路徑七、過去本實驗室的尿素單體之合成途徑 17 路徑八、現今本實驗室的尿素單體之合成途徑 17 路徑九、過去本實驗室的尿素單體之合成總途徑 18 路徑十、現今本實驗室的尿素單體之總合成途徑 18 路徑十一、醯胺基蒽醌類化合物之逆合成分析 19 路徑十二、化合物11之合成途徑 20 路徑十三、化合物12之合成途徑 20 路徑十四、化合物16之合成路徑 21 路徑十五、化合物13之合成途徑 22 路徑十六、化合物14之合成途徑 22 路徑十七、醯胺基蒽醌類化合物之總合成途徑 23 路徑十八、5,8-二羥基醯胺基蒽醌類化合物之總合成途徑 24 路徑十九、脲基蒽醌類化合物之合成途徑 25 路徑二十、化合物24之合成策略 26 路徑二十一、策略A之嘗試合成途徑 27 路徑二十二、策略B之嘗試合成途徑 27 路徑二十三、化合物24之總合成途徑 29 路徑二十四、策略D之嘗試合成途徑 30 圖目錄 圖一、蒽醌類抗腫瘤藥物顯著例子之化學結構 1 圖二、醯胺基蒽醌類化合物之化學結構通式 5 圖三、寡聚仿胜肽顯著例子之化學結構 6 圖四、天然胜肽與寡聚尿素仿胜肽之化學結構 6 圖五、脲基蒽醌類化合物之化學結構通式 7 圖六、胺基蒽醌類化合物之化學結構通式 10 表目錄 表一、比較兩種典型的尿素合成方法 9 表二、合成尿素單體之微波反應條件 15 表三、合成化合物12之反應條件 20 表四、由化合物12得到化合物16的反應條件 21 表五、路徑二十一及二十二之反應條件 28 表六、蒽醌類化合物對人類前列腺癌細胞株的抑制活性 33 | |
| dc.language.iso | zh-TW | |
| dc.subject | 抗腫瘤藥物 | zh_TW |
| dc.subject | 二酮 | zh_TW |
| dc.subject | 蒽 | zh_TW |
| dc.subject | antitumor agent | en |
| dc.subject | anthracenedione | en |
| dc.title | 設計與合成具抗癌潛力之醯胺基、胺基及脲基蒽醌類化合物 | zh_TW |
| dc.title | Design and Synthesis of Amido-, Amino-, and Ureido-anthraquinones as Potential Antitumor Agent | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 93-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 陳基旺,顧記華,林榮信,孔繁璐 | |
| dc.subject.keyword | 抗腫瘤藥物,蒽,二酮, | zh_TW |
| dc.subject.keyword | antitumor agent,anthracenedione, | en |
| dc.relation.page | 175 | |
| dc.rights.note | 未授權 | |
| dc.date.accepted | 2005-07-27 | |
| dc.contributor.author-college | 醫學院 | zh_TW |
| dc.contributor.author-dept | 藥學研究所 | zh_TW |
| 顯示於系所單位: | 藥學系 | |
文件中的檔案:
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-94-1.pdf 未授權公開取用 | 11.11 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。
